Evidence map›Paper›PMID 42756142›Full record

ArticleFrontiers in pharmacology2026

Extracts from

Blanca Elizabeth Hernandez Solano, Joel Daniel Castañeda-Espinoza, Enrique Salas-Vidal, Araceli Guerrero-Alonso, Janette Furuzawa-Carballeda, Carlos Mojica Cardoso, Abraham Noé Anzurez Jiménez, Jessica Nayelli Sánchez-Carranza, Laura Alvarez

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Blanca Elizabeth Hernandez SolanoFacultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
Joel Daniel Castañeda-EspinozaCentro de Desarrollo de Productos Bióticos, Instituto Politécnico Nacional, Yautepec, Morelos, Mexico.
Enrique Salas-VidalDepartamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, Mexico.
Araceli Guerrero-AlonsoCentro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
Janette Furuzawa-CarballedaDepartamento de Cirugía Experimental, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico.
Carlos Mojica CardosoLaboratorio de Patología, Hospital del Niño Morelense, Emiliano Zapata, Morelos, Mexico.
Abraham Noé Anzurez JiménezLaboratorio de Patología, Hospital del Niño Morelense, Emiliano Zapata, Morelos, Mexico.
Jessica Nayelli Sánchez-CarranzaFacultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
Laura AlvarezCentro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chemotherapy resistance is a critical bottleneck in lung cancer treatment, significantly limiting the clinical efficacy of drugs like paclitaxel. This study investigated the cytotoxic and chemosensitizing potential of hexane, acetone, and hydroalcoholic extracts from Methods: Extracts were obtained by maceration and their antiproliferative activity was determined using crystal violet assays. Synergistic interactions between extracts and paclitaxel were quantified using the Chou-Talalay combination index. Mechanistic studies included DAPI staining for nuclear fragmentation, immunofluorescence for P-glycoprotein expression, and flow cytometry to assess functional doxorubicin retention. Chemical profiling was performed via Gas Chromatography-Mass Spectrometry. Results: The hexane extract exhibited the highest intrinsic cytotoxicity (IC Discussion: These findings demonstrate that

Indexed as

chemosensitizationcombination therapyEryngium heterophyllumlung cancernatural extractspaclitaxel

Identifiers

PMID42756142
PMCPMC13582220

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.